Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: " Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. | Retrovirology BioMed Central Research Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias Rienk E Jeeninga1 Barbara Jan1 Henk van den Berg2 and Ben Berkhout 1 Open Access Address laboratory of Experimental Virology Department of Medical Microbiology Center for Infection and Immunity Amsterdam CINIMA Academic Medical Center of the University of Amsterdam Amsterdam The Netherlands and 2Department of Paediatric Oncology Emma Children Hospital Academic Medical Center of the University of Amsterdam Amsterdam The Netherlands Email Rienk E Jeeninga - r.jeeninga@amc.uva.nl Barbara Jan - janbarbara@hotmail.com Henk van den Berg - h.vandenberg@amc.uva.nl Ben Berkhout - b.berkhout@amc.uva.nl Corresponding author Published 27 September 2006 Received 21 July 2006 Accepted 27 September 2006 Retrovirology 2006 3 64 doi l0.ll86 l 742-4690-3-64 This article is available from http www.retrovirology.cOm content 3 1 64 2006 Jeeninga et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract T-cell acute lymphoblastic leukemia T-ALL is a high-risk type of blood-cell cancer. We describe the improvement of a candidate therapeutic virus for virotherapy of leukemic cells. Virotherapy is based on the exclusive replication of a virus in leukemic cells leading to the selective removal of these malignant cells. To improve the safety of such a virus we constructed an HIV-1 variant that replicates exclusively in the presence of the nontoxic effector doxycycline dox . This was achieved by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-derived Tet system for .